Clinical Trials

Trial Name Description
Bayer 16044 Dr. Eric Winquist
An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors k
AZ Strong Dr. Eric Winquist
"not yet open" An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG).
OCTANE MS Dr. S. Welch
Ontario-wide Cancer Targeted Nucleic Acid Evaluation
IND.228 Dr. Eric Winquist
A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours.
GARNET MS Dr. S. Welch
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
ALK4230 Dr. Scott Ernst
"not yet open" A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors.

This information is updated by the Clinical Research Unit

LHSCResearch & Training

Last Updated August 3, 2007 | © 2007, LHSC, London Ontario Canada